S. Rhodes

发表

Identification of extracellular miRNA in human cerebrospinal fluid by next-generation sequencing.

Waibhav Tembe, Susan Rhodes, Kendall Van Keuren-Jensen, 2013, RNA.

The DNA sequence of the human X chromosome

David L. Steffen, R. Durbin, A. Coulson, 2005, Nature.

Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene

Jack R. Davis, D. Bentley, M. Ross, 1998, Nature Genetics.

CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

F. Zhan, B. Barlogie, J. Shaughnessy, 2008, Clinical Cancer Research.

CS 1 , a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

F. Zhan, B. Barlogie, J. Shaughnessy, 2008 .

Identification of transforming growth factor‐β1‐binding protein overexpression in carmustine‐resistant glioma cells by MRNA differential display

S. Rhodes, A. Scheck, D. Hoelzinger, 2000 .

CD4(+)CD25(+) regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis.

F. Shi, W. Piao, D. Campagnolo, 2007, Clinical immunology.

therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis

T. Vollmer, Y. Jee, S. Rhodes, 2007 .

Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits

R. Dubridge, S. Rhodes, V. Ramakrishnan, 2008, Investigational new drugs.

MYELOID NEOPLASIA JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34 + cells in vitro and in vivo

T. Holyoake, A. Whetton, L. Hopcroft, 2014 .

JAK 2 / STAT 5 inhibition by nilotinib with ruxolitinib contributes to the elimination of chronic phase CML CD 34 + cells in vitro and in vivo

T. Holyoake, L. Hopcroft, S. Rhodes, 2014 .

Investigation of JAK2 targets in haematological malignancy

S. Rhodes, 2017 .

Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?

D. Arnold, A. Bar-Or, J. Oger, 2009, Multiple sclerosis.

JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.

Susan Rhodes, Anthony D. Whetton, T. Holyoake, 2014, Blood.

B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis

F. Shi, W. Piao, D. Campagnolo, 2010, Experimental Neurology.

Differential Effects of IL-21 during Initiation and Progression of Autoimmunity against Neuroantigen1

F. Shi, A. La Cava, T. Vollmer, 2005, The Journal of Immunology.

Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.

D. Arnold, L. Weiner, A. Bar-Or, 2007, Archives of neurology.

Neuroantigen and Progression of Autoimmunity against Differential Effects of IL-21 during Initiation

F. Shi, T. Vollmer, S. Rhodes, 2005 .

An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy

W. Liu, Z. Dezső, L. Bigelow, 2022, Nature Cancer.

Modeling Hepatocellular Toxicity of Enavatuzumab, a Humanized Anti-TweakR Antibody

D. Chao, S. Rhodes, G. Starling, 2017 .

Induction of Antigen-Specific Tolerance in Multiple Sclerosis After Immunization With DNA Encoding Myelin Basic Protein in a Randomized, Placebo-Controlled Phase 1/2 Trial

D. Arnold, L. Weiner, A. Bar-Or, 2007 .